Montelukast in the treatment of asthma and beyond

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 639-658

  Diamant, Zuzana ^a   Mantzouranis, Eva ^b   Bjermer, Leif ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CRETE   (Greece)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adults; Allergic rhinitis; Asthma; Children; Leukotriene receptor antagonist; Montelukast; Small airways

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; FLUTICASONE PROPIONATE; LONG ACTING DRUG; LORATADINE; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; PREDNISOLONE; SALBUTAMOL; SALMETEROL; SINGULAIR PEDIATRIC; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ASTHMA; BRONCHIOLITIS; BRONCHITIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE INDUCED ASTHMA; FEVER; GASTROENTERITIS; HAY FEVER; HEADACHE; HUMAN; INFLUENZA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; PHARYNGITIS; PNEUMONIA; QUALITY OF LIFE; REVIEW; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUSITIS; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; WHEEZING;

EID: 77949779450     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.62     Document Type: Review

References (153)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burDen of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469-478 (2004).
2. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir. Med. 95(9), 703-719 (2001).
3. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen). Allergy 63(Suppl. 86), 8-160 (2008).
4. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 120(6), 1269-1275 (2007).
5. Kyllönen H, Malmberg P, Remitz A et al. Respiratory symptoms, bronchial hyper-responsiveness, and eosinophilic airway inflammation in patients with moderate-to-severe atopic dermatitis. Clin. Exp. Allergy 36(2), 192-197 (2006).
6. Ten Brinke A, Ouwerkerk ME, Zwinderman AH, Spinhoven P, Bel EH. Psychopathology in patients with severe asthma is associated with increased health care utilization. Am. J. Respir. Crit. Care Med. 163(5), 1093-1096 (2001).
7. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J. Allergy Clin. Immunol. 104(2 Pt 1), 301-304 (1999).
8. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J. Allergy Clin. Immunol. 109(3), 419-425 (2002).
9. Greisner WA, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 19(4), 185-188 (1998).
10. Bousquet J, Gaugris S, Kocevar VS et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy corrected. Clin. Exp. Allergy 35(6), 723-727 (2005).
11. Ponte EV, Franco R, Nascimento HF et al. Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. Allergy 63(5), 564-569 (2008).
12. Chanez P, Vignola AM, Vic P et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am. J. Respir. Crit. Care Med. 159(2), 588-595 (1999).
13. Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C. Exhaled nitric oxiDe in seasonal allergic rhinitis: influence of pollen season and therapy. Clin. Exp. Allergy 31(3), 409-416 (2001).
14. De Benedictis FM, Vaccher S, De Benedictis D. Montelukast sodium for exerciseinduced asthma. Drugs Today (Barc.) 44(11), 845-855 (2008).
15. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346(22), 1699-1705 (2002).
16. Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymasepositive mast cells and lung function in severe asthma. Am. J. Respir. Crit. Care Med. 171(5), 431-439 (2005).
17. Dolhnikoff M, da Silva LF, De Araujo BB et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J. Allergy Clin. Immunol. (2009) (Epub ahead of print).
18. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir. Med. 101(3), 378-388 (2007).
19. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 170(8), 836-844 (2004).
20. Bourdin A, Paganin F, Préfaut C, Kieseler D, Godard P, Chanez P. Nitrogen washout slope in poorly controlled asthma. Allergy 61(1), 85-89 (2006).
21. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med. 149(4 Pt 1), 953-959 (1994).
22. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum eicosanoid concentrations in asthma. Am. J. Respir. Crit. Care Med. 160(6), 1905-1909 (1999).
23. Feldberg W, Kellaway CH. Liberation of histamine and formation of lyscithin-like substances by cobra venom. J. Physiol. 94, 187-226 (1938).
24. Kellaway CH, Trethewie ER. The liberation of a slow reacting smooth-muscle stimulating substance in anaphylaxis. Q. J. Exp. Physiol. 30(2), 121-145 (1940).
25. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 173(3), 1503-1510 (2004).
26. Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-GolDen M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. J. Immunol. 179(8), 5454-5461 (2007).
27. Lynch KR, ONeill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399(6738), 789-793 (1999).
28. Sarau HM, Ames RS, Chambers J et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56(3), 657-663 (1999).
29. Hay DW. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 111(2 Suppl.), 35S-45S (1997).
30. Yang G, Haczku A, Chen H et al. Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am. J. Physiol. Lung Cell Mol. Physiol. 286(5), L992-L1001 (2004).
31. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341(8851), 989-990 (1993).
32. Diamant Z, Hiltermann JT, Van Rensen EL et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med. 155(4), 1247-1253 (1997).
33. Altraja S, Kadai M, Rekker E, Altraja A. Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. Respir. Res. 9, 44 (2008).
34. Abdulamir AS, Hafidh RR, Abubakar F. Different inflammatory mechanisms in lungs of severe and mild asthma: crosstalk of NF-k-B, TGFb1, Bax, Bcl-2, IL-4 and IgE. Scand. J. Clin. Lab. Invest. (2009) (Epub ahead of print).
35. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142(1), 112-119 (1990).
36. Diamant Z, Sampson AP. Antiinflammatory mechanisms of leukotriene modulators. Clin. Exp. Allergy 29(11), 1449-1453 (1999).
37. Georgitis JW, Matthews BL, Stone B. Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage fluid. Int. Arch. Allergy Immunol. 106(4), 416-421 (1995).
38. Pawankar R, Zernotti ME. Rhinosinusitis in children and asthma severity. Curr. Opin. Allergy Clin. Immunol. 9(2), 151-153 (2009).
39. Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study. Pediatrics 108(2), E33 (2001).
40. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. 98(6 Pt 1), 1051-1057 (1996).
41. Jackson DJ, Gangnon RE, Evans MD et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 178(7), 667-672 (2008).
42. Kusel MM, De Klerk NH, Kebadze T et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J. Allergy Clin. Immunol. 119(5), 1105-1110 (2007).
43. Piedimonte G, Renzetti G, Auais A et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr. Pulmonol. 40, 285-291 (2005).
44. De Lepeleire I, Reiss TF, Rochette F et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin. Pharmacol. Ther. 61(1), 83-92 (1997).
45. Reiss TF, Sorkness CA, Stricker W et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52(1), 45-48 (1997).
46. Kelly MM, Chakir J, Vethanayagam D et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130(3), 741-753 (2006).
47. Migoya E, Kearns GL, Hartford A et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J. Clin. Pharmacol. 44(5), 487-494 (2004).
48. Sampson AP, Diamant Z. Monograph on montelukast. J. Drug Evaluation 1(2), 53-88 (2002).
49. Muijsers RB, Noble S. Spotlight on montelukast in asthma in children 2 to 14 years of age. Am. J. Respir. Med. 1(3), 225-228 (2002).
50. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. 25(9), 1022-1031 (1997).
51. Ravasi S, Capra V, Panigalli T, Rovati GE, Nicosia S. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem. Pharmacol. 63(8), 1537-1546 (2002).
52. Jones TR, Labelle M, Belley M et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 73(2), 191-201 (1995).
53. Dahlén SE, Malmström K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(1), 9-14 (2002).
54. Diamant Z, Grootendorst DC, Veselic- Charvat M et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin. Exp. Allergy 29(1), 42-51 (1999).
55. Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339(3), 147-152 (1998).
56. Villaran C, ONeill SJ, Helbling A et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/ Salmeterol Exercise Study Group. J. Allergy Clin. Immunol. 104(3 Pt 1), 547-553 (1999).
57. Edelman JM, Turpin JA, Bronsky EA et al. Oral montelukast compared with inhaled salmeterol to prevent exerciseinduced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med. 132(2), 97-104 (2000).
58. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 98(11), 1051-1062 (2004).
59. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 14(1), 12-18 (1999).
60. Jayaram L, Pizzichini E, Lemière C et al. Steroid naive eosinophilic asthma: antiinflammatory effects of fluticasone and montelukast. Thorax 60(2), 100-105 (2005).
61. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebocontrolled trial. Lancet 357(9273), 2007-2011 (2001).
62. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327(7420), 891 (2003).
63. Braccioni F, Dorman SC, OByrne PM et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J. Allergy Clin. Immunol. 110(1), 96-101 (2002).
64. Ghiro L, Zanconato S, Rampon O, PioVan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxiDe in asthmatic children. Eur. Respir. J. 20(3), 630-634 (2002).
65. Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin. Ther. 30, 1026-1035 (2008).
66. Holgate ST, Peters-GolDen M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. 111(Suppl. 1), S18-S34 (2003).
67. Walters EH, Reid DW, Johns DP, Ward C. Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. Eur. Respir. J. 30(3), 574-588 (2007).
68. Riccioni G, Vecchia RD, DOrazio N, Sensi S, Guagnano MT. Comparison of montelukast and budesoniDe on bronchial reactivity in subjects with mild-moderate persistent asthma. Pulm. Pharmacol. Ther. 16(2), 111-114 (2003).
69. Zeidler MR, Kleerup EC, Goldin JG et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur. Respir. J. 27(2), 307-315 (2006).
70. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulm. Pharmacol. Ther. 20(6), 691-700 (2007).
71. Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxiDe of alveolar and bronchial origin in inhaled corticosteroidtreated asthma. Respir. Med. 103(2), 296-300 (2009).
72. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann. Allergy Asthma Immunol. 97(6), 731-741 (2006).
73. Bjermer L, Diamant Z. Complementary therapy in asthma: inhaled corticosteroids and what? Curr. Opin. Pulm. Med. 15(1), 46-51 (2009).
74. Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 130(6), 1726-1732 (2006).
75. Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J. Allergy Clin. Immunol. 103(2 Pt 1), 232-237 (1999).
76. Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. Am. J. Respir. Crit. Care Med. 163(7), 1551-1556 (2001).
77. Boot JD, Panzner P, Diamant Z. A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma. Pulm. Pharmacol. Ther. 20(3), 201-219 (2007).
78. Boot JD, Chandoesing P, De Kam ML et al. Applicability and reproducibility of biomarkers for the evaluation of antiinflammatory therapy in allergic rhinitis. J. Invest. Allergol. Clin. Immunol. 18(6), 433-442 (2008).
79. Noonan MJ, Chervinsky P, Brandon M et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J. 11(6), 1232-1239 (1998).
80. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158(11), 1213-1220 (1998).
81. Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. 130(6), 487-495 (1999).
82. Israel E, Chervinsky PS, Friedman B et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol. 110(6), 847-854 (2002).
83. Baumgartner RA, Martinez G, Edelman JM et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur. Respir. J. 21(1), 123-128 (2003).
84. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur. Respir. J. 20(4), 853-858 (2002).
85. Zeiger RS, Szefler SJ, Phillips BR et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J. Allergy Clin. Immunol. 117(1), 45-52 (2006).
86. Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesoniDe on control of mild to moderate asthma. Thorax 58(3), 204-210 (2003).
87. Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesoniDe versus double dose inhaled budesoniDe in adult patients with asthma. Thorax 58(3), 211-216 (2003).
88. Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 61(6), 737-742 (2006).
89. Kaminsky DA, Bates JH, Irvin CG. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma. Am. J. Respir. Crit. Care Med. 162(1), 179-186 (2000).
90. Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L. Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Chest 126(4), 1154-1160 (2004).
91. Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann. Allergy Asthma Immunol. 88(4 Suppl. 1), 23-29 (2002).
92. Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin. Exp. Allergy 32(1), 126-132 (2002).
93. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol. 88(6), 592-600 (2002).
94. Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 20(10), 1549-1558 (2004).
95. Grossman J. One airway, one disease. Chest 111(2 Suppl.), 11S-16S (1997).
96. Rönmark E, Lindberg A, Watson L, Lundbäck B. Outcome and severity of adult onset asthma - report from the obstructive lung disease in northern SweDen studies (OLIN). Respir. Med. 101(11), 2370-2377 (2007).
97. Murray CS. Can inhaled corticosteroids influence the natural history of asthma? Curr. Opin. Allergy Clin. Immunol. 8(1), 77-81 (2008).
98. Selroos O. Effect of disease duration on dose-response of inhaled budesoniDe in asthma. Respir. Med. 102(7), 1065-1072 (2008).
99. Berry M, Hargadon B, Morgan A et al. Alveolar nitric oxiDe in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J. 25(6), 986-991 (2005).
100. Kato J, Kohyama T, Okazaki H et al. Leukotriene D4 potentiates fibronectininduced migration of human lung fibroblasts. Clin. Immunol. 117(2), 177-181 (2005).
101. Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. J. Respir. Cell. Mol. Biol. 19(3), 453-461 (1998).
102. Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am. J. Respir. Cell. Mol. Biol. 29(6), 683-693 (2003).
103. Henderson WR, Tang LO, Chu SJ et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am. J. Respir. Crit. Care Med. 165(1), 108-116 (2002).
104. Henderson WR, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med. 173(7), 718-728 (2006).
105. Pifferi M, Caramella D, Ragazzo V, De Marco E, Pietrobelli A, Boner AL. Montelukast and airway remodeling in children with chronic persistent asthma: an open study. Pediatr. Allergy Immunol. 15(5), 472-473 (2004).
106. Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 279(15), 1181-1186 (1998).
107. Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr. Med. Res. Opin. 20(10), 1651-1659 (2004).
108. Simons FE, Villa JR, Lee BW et al. Montelukast added to budesoniDe in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr. 138(5), 694-698 (2001).
109. Karaman O, Sünneli L, Uzuner N et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol. Immunopathol. (Madr.) 32(1), 21-27 (2004).
110. Taylor IK, Wellings R, Taylor GW, Fuller RW. Urinary leukotriene E4 excretion in exercise-induced asthma. J. Appl. Physiol. 73(2), 743-748 (1992).
111. Carraro S, Corradi M, Zanconato S et al. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 115(4), 764-770 (2005).
112. Peroni DG, Piacentini GL, Pietrobelli A et al. The combination of single-dose montelukast and loratadine on exerciseinduced bronchospasm in children. Eur. Respir. J. 20(1), 104-107 (2002).
113. Melo RE, Solé D, Naspitz CK. Exerciseinduced bronchoconstriction in children: montelukast attenuates the immediatephase and late-phase responses. J. Allergy Clin. Immunol. 111(2), 301-307 (2003).
114. Kim JH, Lee SY, Kim HB et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr. Pulmonol. 39(2), 162-166 (2005).
115. De Benedictis FM, Del Giudice MM, Forenza N, Decimo F, De Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur. Respir. J. 28(2), 291-295 (2006).
116. Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J. Allergy Clin. Immunol. 121(2), 383-389 (2008).
117. Phipatanakul W, Greene C, Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann. Allergy Asthma Immunol. 91(1), 49-54 (2003).
118. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 116(2), 360-369 (2005).
119. Kumar V, Ramesh P, Lodha R, Pandey RM, Kabra SK. Montelukast vs. inhaled low-dose budesoniDe as monotherapy in the treatment of mild persistent asthma: a randomized double blind controlled trial. J. Trop. Pediatr. 53(5), 325-330 (2007).
120. Spahn JD, Covar RA, Jain N et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann. Allergy Asthma Immunol. 96(4), 541-549 (2006).
121. Nieto A, Pamies R, Oliver F, Medina A, Caballero L, Mazon A. Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study). Respir. Med. 100(7), 1180-1185 (2006).
122. Verini M, Peroni DG, Piacentini GL et al. Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxiDe as outcome measures. Allergy Asthma Proc. 28(6), 691-694 (2007).
123. Miraglia Del Giudice M, Piacentini GL, Capasso M et al. Formoterol, montelukast, and budesoniDe in asthmatic children: effect on lung function and exhaled nitric oxide. Respir. Med. 101(8), 1809-1813 (2007).
124. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J. Allergy Clin. Immunol. 121(6), 1365-1371 (2008).
125. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115(2), 233-242 (2005).
126. Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108(3), E48 (2001).
127. Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 171(4), 315-322 (2005).
128. Bisgaard H, Flores-Nunez A, Goh A et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am. J. Respir. Crit. Care Med. 178(8), 854-860 (2008).
129. Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin. Ther. 26(11), 1895-1904 (2004).
130. Kooi EM, Schokker S, Marike Boezen H et al. Fluticasone or montelukast for preschool children with asthma-like symptoms: randomized controlled trial. Pulm. Pharmacol. Ther. 21(5), 798-804 (2008).
131. Straub DA, Moeller A, Minocchieri S et al. The effect of montelukast on lung function and exhaled nitric oxiDe in infants with early childhood asthma. Eur. Respir. J. 25(2), 289-294 (2005).
132. Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 131(1), 180-186 (2007).
133. Robertson CF, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 175(4), 323-329 (2007).
134. Johnston NW, Mandhane PJ, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120(3), e702-e712 (2007).
135. Amirav I, Luder AS, Kruger N et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 122(6), e1249-e1255 (2008).
136. Bacharier LB, Phillips BR, Zeiger RS et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J. Allergy Clin. Immunol. 122(6), 1127-1135.e8 (2008).
137. Brand PL, Baraldi E, Bisgaard H et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur. Respir. J. 32(4), 1096-1110 (2008)
138. Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J. Allergy Clin. Immunol. 115(1), 47-54 (2005).
139. Dal Negro RW, Borderias L, Zhang Q et al. Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis. BMC Pulm. Med. 9, 10 (2009).
140. Korn D, Van Den BranDe P, Potvin E, Dramaix M, Herbots E, Peché R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr. Med. Res. Opin. 25(2), 489-497 (2009).
141. Storms W, Michele TM, Knorr B et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin. Exp. Allergy 31(1), 77-87 (2001).
142. Chervinsky P, Philip G, Malice MP et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann. Allergy Asthma Immunol. 92(3), 367-373 (2004).
143. Bakhireva LN, Jones KL, Schatz M et al. Safety of leukotriene receptor antagonists in pregnancy. J. Allergy Clin. Immunol. 119(3), 618-625 (2007).
144. Becker AB, Kuznetsova O, Vermeulen J et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann. Allergy Asthma Immunol. 96(6), 800-807 (2006).
145. Pedersen S, Agertoft L, Williams-Herman D et al. Placebo-controlled study of montelukast and budesoniDe on short-term growth in prepubertal asthmatic children. Pediatr. Pulmonol. 42(9), 838-843 (2007).
146. Loughlin JE, Cole JA, Rothman KJ, Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann. Allergy Asthma Immunol. 88(3), 319-325 (2002).
147. Hauser T, Mahr A, Metzler C et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 63(8), 677-682 (2008).
148. Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J. Allergy Clin. Immunol. 122(4), 828-829 (2008).
149. Strine TW, Mokdad AH, Balluz LS, Berry JT, Gonzalez O. Impact of depression and anxiety on quality of life, health behaviors, and asthma control among adults in the United States with asthma, 2006. J. Asthma 45(2), 123-133 (2008).
150. Holgate S, Bisgaard H, Bjermer L et al. The Brussels Declaration: the need for change in asthma management. Eur. Respir. J. 32(6), 1433-1442 (2008).
151. Wohlsen A, Martin C, Vollmer E et al. The early allergic response in small airways of human precision-cut lung slices. Eur. Respir. J. 21(6), 1024-1032 (2003).
152. ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J. 26(5), 812-818 (2005).
153. Haldar P, Pavord ID, Shaw De et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178(3), 218-224 (2008).